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Although essential for a successful pregnancy, a growing body of evidence suggests thatmaternal inflammation, whendysregulated,
may represent a risk factor for both maternal and neonatal outcomes. Here, we assessed the accuracy of maternal C-reactive
protein (CRP) concentrations at the middle phase of pregnancy in the identification of maternal adverse outcomes (MAO) until
delivery. A correlation betweenCRP and a complicated pregnancy including bothmaternal andneonatal adverse outcomes has been
investigated, too. In this retrospective study, conducted at the DiabetologyUnit of IRCCS Ospedale Policlinico SanMartino, Genoa
(Italy), 380 outpatient pregnant women have been enrolled at the prenatal visit before performing a 75 g oral glucose tolerance
test at 24th-26th gestational week for gestational diabetes mellitus (GDM) screening. Demographic, medical, and reproductive
history has been obtained by verbal interview. Data about pregnancy and delivery have been retrieved from medical records. The
median value of maternal baseline serum CRP was 3.25𝜇g/mL. Women experiencing MAO were older, more frequently suffering
from hypertension, and showed higher CRP concentrations, with a cutoff value >1.86 𝜇g/mL found by a ROC curve analysis to be
accurately predictive for MAO. By a logistic regression analysis, serum CRP levels >1.86 𝜇g/mL have been found to predict MAO
also consideringmaternal age, hypertension, andGDM.Maternal CRP levels have been positively associatedwith overall pregnancy
adverse outcomes (maternal and neonatal), too. In conclusion, in pregnant women serum levels of CRP can early recognize subjects
at higher risk for maternal and neonatal complications needing a more stringent follow-up.
1. Introduction
Inflammation is an essential element for a successful preg-
nancy [1]. Indeed, inflammatory processes are involved in
implantation and decidualization during early stages of
pregnancy, but also in the uterine activation during labor
[1–3]. However, in the middle phase of gestation, a qui-
escence of inflammation is required to ensure maternal
tolerance for fetal antigens [4]. A growing body of evi-
dence suggests that a dysregulated maternal inflammation
during pregnancy might be a possible risk factor for sev-
eral neonatal complications [5, 6]. Moreover, some studies
have found a correlation between inflammation and the
development of gestational complications [7, 8]. The iden-
tification of a low-cost and easy-to-measure biomarker of
maternal inflammation able to predict risk for complicated
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pregnancy might allow a better surveillance during gesta-
tion.
C-reactive protein (CRP) is routinely used in the diag-
nosis and clinical monitoring of infections, included those
occurring in the obstetric field [9–11]. CRP is also an impor-
tant biomarker of sterile inflammation, commonly evaluated
for monitoring treatment response and predicting long-term
outcome in inflammatory diseases [12, 13].
Although the topic has been largely investigated, the pur-
pose of this study is to examine whether maternal serumCRP
concentrations in a specific period of the pregnancy—the
middle phase—may help in predicting late gestational com-
plications until delivery, considering the large diffusion and
the extreme easiness in measuring this biomarker, largely
validated in the cardiovascular field.
2. Materials and Methods
2.1. Study Population and Clinical Assessment. This retro-
spective study was conducted between October 2012 and
November 2014 among 380 consecutive outpatient pregnant
women aged 18 or older attending the Diabetology Unit of
IRCCS Ospedale Policlinico San Martino (Genoa, Italy) to
perform a 75-g oral glucose tolerance test (OGTT) for the
screening of gestational diabetes (GDM), as prescribed by
current guidelines [14], between the 24th and 26th gestational
week (gestational age 24 weeks+0 days – 25 weeks+6 days).
The only exclusion criterion was the detection or the clinical
suspicion of an active infection. The Ethics Committee of
IRCCS Ospedale Policlinico San Martino in Genoa (Italy)
approved this protocol, performed in accordance with the
guidelines of the Declaration of Helsinki. Patients gave
written informed consent before entering the study.
Serum samples were collected during the prenatal visit
at baseline before the OGTT and stored in a locked and
temperature-controlled freezer at −80∘C according to Good
Clinical Practice and Good Clinical Laboratory Practice
guidelines until analysis [15, 16]. Demographic, medical, and
reproductive history was obtained by verbal interview. Data
about pregnancy complications, time and type of delivery,
and neonatal characteristics at birth were retrieved from
medical records.
2.2. Definition of Gestational Diabetes Mellitus and Maternal
and Neonatal Outcomes. GDM has been defined according
to latest American Diabetes Association diagnostic criteria
[14]. In the present study, in accordance with a previous
study conducted in an Italian cohort [17], maternal adverse
outcomes (MAO) included the following conditions:
gestational hypertension, premature delivery (before 37th
gestational week), and Cesarean delivery. Neonatal outcomes
included macrosomia, fetal distress/polyhydramnios, need
for neonatal resuscitation, and small and/or large baby size
for gestational age (as defined by the upper or lower 10% of
Italian birth weight and length percentiles). Neonatal weight
and length percentiles were calculated using online neonatal
anthropometric charts developed specifically for the Italian
population available at http://www.inescharts.com. Ponderal
index was calculated by the following equation: (birth weight
in grams x 100)/crown-heel length in cubic centimeters [18];
values higher than 2.85 were considered excessive [19].
2.3. Study Endpoints. The primary endpoint was to deter-
minewhether CRP serum levels could predict the appearance
of MAO from the 24th-26th week of gestation until delivery.
The secondary endpoint was to evaluate the role of CRP in
the association with a complicated pregnancy by considering
both maternal and neonatal adverse outcomes.
2.4. Detection of Inflammatory, Circulating Biomarker Serum
Levels. Serum levels CRP were measured by colorimetric
enzyme-linked immunosorbent assay (ELISA) following the
manufacturer’s instructions (R&D Systems, Minneapolis,
MN).The limit of detection was 15.625 pg/mL for CRP. Mean
intra- and interassay coefficients of variation were <8%.
2.5. Statistical Analysis. Analyses were performed using
IBM SPSS Statistics for Windows, Version 23.0 (IBM CO.,
Armonk, NY). Categorical data are presented as relative and
absolute frequencies and comparedwithChi-square or Fisher
exact test, while continuous variables are shown as median
and interquartile range (IQR) and their comparison was done
by non-parametric Mann–Whitney 𝑈 test. The prognostic
ability of CRP toward the prediction of pregnancy outcomes
was evaluated by a receiver operator characteristic (ROC)
curve. The area under the curve (AUC) was given with 95%
confidence interval (CI) and the cutoff point of CRP was
calculated maximizing the sensitivity in accordance with
the Youden’s index. The predictive ability of CRP toward
MAO was calculated by a logistic regression. The association
between CRP and overall pregnancy adverse outcomes (both
maternal and neonatal) was calculated by a linear regression.
In the multivariate model, we adjusted for maternal age
at the time of OGTT, presence of hypertension, and the
development of GDM. For all statistical analyses, a 2-sided
𝑝-value <0.05 was considered as statistically significant.
3. Results
3.1. Patients’ Characteristics. Baseline characteristics of the
overall cohort are shown in Table 1. Pregnant women median
age at the time of enrollmentwas 34 (31-37), with a remarkable
prevalence of Caucasian patients (90.7%).Median bodymass
index (BMI) before pregnancy was 21.19 (19.82-26.63), with
a median weight gain at delivery of 12 kg (10-15). In 45
women (11.9%), glucose values at different time points of
OGTT met criteria for GDM. Most frequent complications
among women were Cesarean delivery (50.6%) and prema-
ture delivery (9.4%). Among babies, most frequent adverse
outcomes included small size for gestational age (22.4%),
macrosomia (2.9%), and the need for resuscitation (1.7%), as
shown in Table 1. The median value of maternal serum CRP
was 3.25𝜇g/mL (1.61-8.07).
3.2. CRP Serum Levels and Maternal Adverse Outcomes. We
then evaluated the characteristics of the overall cohort by
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Table 1: Baseline characteristics of the overall cohort.
Overall cohort (n=380)
Demographic and clinical characteristics
Age at enrollment, years (IQR) 34 (31-37)
CRP∗, 𝜇g/mL (IQR) 3.25 (1.61-8.07)
Ethnicity
Caucasian, n (%) 342 (90.7)
Latin American, n (%) 20 (5.3)
African, n (%) 6 (1.6)
Indian, n (%) 9 (2.4)
BMI§, kg/m2 (IQR) 21.19 (19.82-26.63)
Underweight, n (%) 22 (9.2)
Normal weight, n (%) 176 (73.6)
Overweight, n (%) 37 (15.5)
Obese, n (%) 10 (4.1)
Weight gain at delivery, kg (IQR) 12 (10-15)
Comorbidities
Thyroid disease, n (%) 28 (7.4)
Hypertension, n (%) 8 (2.1)
PCOS¥, n (%) 7 (1.8)
Coagulation/PLTΦ diseases, n (%) 8 (2.1)
Autoimmune diseases, n (%) 35 (9.2)
GDM#, n (%) 45 (11.9)
Therapy
Thyroid hormone replacement therapy, n (%) 27 (7.1)
Corticosteroid hormone, n (%) 9 (2.4)
Aspirin, n (%) 16 (4.2)
Pregnancy and delivery characteristics
Gestational hypertension, n (%) 5 (1.3)
Premature delivery, n (%) 32 (9.4)
Cesarean delivery, n (%) 177 (50.6)
Urgent Cesarean delivery, n (%) 40 (11.4)
Gestational age at delivery, days (IQR) 275 (270-282)
Overall maternal adverse outcomes 189 (49.7)
Baby characteristics
Baby weight, g (IQR) 3280 (2948.75-3571.25)
Baby length, cm (IQR) 49 (48-50)
Small for gestational age, n (%) 74 (22.4)
Large for gestational age, n (%) 23 (6.9)
Ponderal index (IQR) 2.75 (2.56-2.94)
Macrosomy, n (%) 10 (2.9)
Apgar score
0, n (%) 1 (0.3)
3, n (%) 1 (0.3)
4, n (%) 1 (0.3)
5, n (%) 1 (0.3)
6, n (%) 1 (0.3)
7, n (%) 2 (0.6)
8, n (%) 4 (1.2)
9, n (%) 23 (6.8)
10, n (%) 306 (90)
Resuscitation, n (%) 6 (1.7)
Fetal distress/polyhydramnios, n (%) 3 (0.8)
Overall neonatal adverse outcomes, n (%) 173 (45.5)
Maternal and neonatal adverse outcomes, n (%) 272 (71.6)
Data are expressed as median (interquartile range [IQR], number [n], or percentage [%]).
∗ CRP: C-reactive protein.
§ BMI: body mass index.
¥ PCOS: polycystic ovary syndrome.
Φ PLT: platelets.
# GDM: gestational diabetes mellitus.
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comparing patients according to the presence or absence
of MAO (Table 2). Women who experienced MAO were
older andmore frequently suffered fromhypertension.When
analyzing inflammatory mediators, CRP serum levels were
significantly higher in the MAO group and babies born
from mothers with MAO were smaller (Table 2). Apgar
scores of babies born from mothers with MAO were lower;
accordingly, all cases of neonatal resuscitation occurred in
this group (Table 2).
3.3. High CRP Serum Levels and Prediction of Maternal and
Neonatal Adverse Outcomes. By a ROC curve analysis, we
found maternal CRP serum levels during pregnancy to hold
significant prognostic accuracy towards MAO occurrence
(AUC0.624 [95%CI 0.573-0.672];𝑝 < 0.001, Figure 1). ACRP
value >1.86 𝜇g/mL was found as the best cutoff point, having
a sensitivity of 79.9% and a specificity of 41.4% (Figure 1).
By a logistic regression analysis, we could show serum
CRP levels >1.86 𝜇g/mL to predict MAO occurrence (OR
2.80, 95% CI 1.77-4.43, 𝑝 <0.001), as shown in Table 3.
This result was confirmed also in the multivariate model
considering maternal age, hypertension, and the develop-
ment of GDM during pregnancy (OR 3.73, 95% CI 2.02-6.86,
𝑝 <0.001, and Table 3). We further investigated the impact of
CRP on all adverse outcomes, both maternal and neonatal.
Indeed, CRP values were positively associated with preg-
nancy adverse outcomes both in the univariate (𝛽=0.043, 95%
CI 0.003-0.083, p=0.036) and in the multivariate model when
maternal age, hypertension, and development of GDM were
considered (𝛽=0.05, 95% CI 0.010-0.090, 𝑝=0.015, Table 4).
4. Discussion
The main finding of this study is that maternal serum levels
of CRP during the second trimester of pregnancy represent
a useful predictor of MAO occurrence. Moreover, a positive
association between maternal CRP levels and the composite
endpoint including both maternal and neonatal adverse
outcomes has been demonstrated. These results are in accor-
dance with prior studies exploring the association between
CRP and pregnancy adverse outcomes [20–25]. In particular,
Sorokin and colleagues found an association between mater-
nal CRP (median level 68.52𝜇g/mL) and preterm delivery
in 495 pregnant women at increased risk for spontaneous
preterm delivery who were already administered with cor-
ticosteroids [22]. Similarly, Pitiphat et al. demonstrated that
women with CRP serum levels ≥8mg/L had a greater risk of
preterm delivery [21]. Differently from other studies [20–23],
we found a lower CRP threshold above which adverse events,
especially the maternal ones, complicated the pregnancy.
Ertas and coworkers described a CRP cutoff of 9.66mg/L,
which was associated with the severity of the clinical risk
of pre-eclampsia and with adverse neonatal outcome [20].
Since these levels are extremely higher than ours, a potential
explanation might be the presence in our cohort of cases of
gestational hypertension only, while no woman developed
pre-eclampsia, thus limiting the comparison of results. More-
over, CRP has been measured at different time points. While
AUC: 0.624
p <0.001
Youden’s index: 0.2126
Cutoﬀ: >1.86 g/mL
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20 40 60 80 1000
100-Speciﬁcity
0
20
40
60
80
100
Se
ns
iti
vi
ty
Figure 1: The receiver operator characteristic (ROC) curve analysis
for C-reactive protein towards the occurrence of maternal adverse
outcomes from the second trimester of pregnancy until delivery is
shown.
Pitiphat et al. and Tjoa et al. measured CRP during the first
trimester, Ertas et al. and Sorokin et al. evaluated it between
second and third trimester. Indeed, inflammation is known to
increase early for implantation and then to reduce during the
middle phase of pregnancy due to maternal tolerance to fetal
antigens [26]. Taken together, when compared to previous
investigations, our findings are likely to highlight that even
a little increase in the degree of systemic inflammation can
represent an additional risk for the development of pregnancy
complications, both for mother and baby.
Additionally, in a recent study women who had a preterm
delivery or gave birth to a baby small for gestational age
showed an increased risk for premature cardiac disease or
death [27]. This finding is of great interest, suggesting a
possible correlation between the inflammatory milieu of the
middle phase of gestation, associated with adverse pregnancy
outcomes, and the inflammatory burden of women’s rest of
life, usually correlated with the development of cardiovas-
cular diseases. This evidence has a practical consequence
because the identification of women with a higher degree of
inflammation during gestation could help in preventing not
also pregnancy complications, but also future cardiovascular
events.
Age is a well-known risk factor for the development
of MAOs during pregnancy [28–30]. Similarly, GDM and
gestational hypertension are associated with an increased risk
ofmaternal and neonatal adverse outcomes, especially in case
of inadequate glycemic and pressure control [30, 31]. Espe-
cially GDM is a recognized risk factor for pregnancy-related
complications [32] affecting both the mother by increasing
the incidence of pre-eclampsia, gestational hypertension, and
polyhydramnios [33] and the fetus by favoring the occurrence
of macrosomia, prematurity, need for neonatal intensive care
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Table 2: Characteristics of the cohort according to maternal adverse outcomes.
No maternal adverse outcomes (n=191) Maternal adverse outcomes (n=189) p
Demographic and clinical characteristics
Age at enrollment, years (IQR) 33 (30-36) 35 (32-38) <0.001
CRP∗, 𝜇g/mL (IQR) 2.51 (1.16-6.11) 4.40 (2.03-10.1) <0.001
Ethnicity 0.102
Caucasian, n (%) 167 (88.4) 175 (93.1)
Latin American, n (%) 11(5.8) 9 (4.8)
African, n (%) 4 (2.1) 2 (1.1)
Indian, n (%) 7 (3.7) 2 (1.1)
BMI§, kg/m2 (IQR) 21.01 (19.79-22.95) 21.48 (19.83-24.22) 0.145
Underweight, n (%) 12 (9.7) 10 (8.7)
Normal weight, n (%) 96 (77.4) 80 (69.6)
Overweight, n (%) 12 (9.7) 19 (16.5)
Obese, n (%) 4 (3.2) 6 (5.2)
Weight gain at delivery, kg (IQR) 13 (11-16) 12 (9-15) 0.179
Comorbidities
Thyroid disease, n (%) 12 (6.3) 16 (8.5) 0.416
Hypertension, n (%) 1 (0.5) 7 (3.7) 0.031
PCOS¥, n (%) 1 (0.5) 6 (3.2) 0.055
Coagulation/PLTΦ diseases, n (%) 2(1) 6 (3.2) 0.149
Autoimmune diseases, n (%) 17 (8.9) 18 (9.5) 0.834
GDM#, n (%) 18 (9.5) 27 (14.3) 0.153
Therapy
Thyroid hormone replacement therapy, n (%) 12 (6.3) 15 (7.9) 0.531
Corticosteroid hormone, n (%) 4 (2.1) 5 (2.6) 0.724
Aspirin, n (%) 4 (2.1) 12 (6.3) 0.039
Pregnancy and delivery characteristics
Gestational hypertension, n (%) 0 5 (2.6) 0.024
Premature delivery, n (%) 0 32 (17.4) <0.001
Cesarian delivery, n (%) 0 177 (93.7) <0.001
Urgent caesarian delivery, n (%) 0 40 (21.2) <0.001
Gestational age at delivery, days (IQR) 280 (273-285) 273 (267-279) <0.001
Baby characteristics
Baby weight, g (IQR) 3300 (3040-3595) 3210 (2860-3535) 0.046
Baby length, cm (IQR) 49 (48-51) 49 (47-50) 0.015
Small for gestational age, n (%) 38 (24.5) 36 (20.6) 0.392
Large for gestational age, n (%) 7 (4.5) 16 (9.1) 0.097
Ponderal index (IQR) 2.76 (2.55-2.97) 2.75 (2.56-2.94) 0.898
Macrosomy, n (%) 4 (2.4) 6 (3.2) 0.660
Apgar score <0.001
0, n (%) 1 (0.6)
3, n (%) 1 (0.6)
4, n (%) 1 (0.6)
5, n (%) 1 (0.6)
6, n (%) 1 (0.6)
7, n (%) 2 (1.1)
8, n (%) 4 (2.2)
9, n (%) 5 (3.1) 18 (10)
10, n (%) 155 (96.9) 151 (83.9)
Resuscitation, n (%) 0 6 (3.2) 0.022
Fetal distress/polyhydramnios, n (%) 1 (0.5) 2 (1.1) 0.557
Overall neonatal adverse outcomes, n (%) 83 (43.5) 90 (47.6) 0.416
Data are expressed as median (interquartile range [IQR], number [n], or percentage [%]).
p-values were calculated according to Chi-square or Fisher exact test or Mann-Whitney 𝑈 test when appropriate and referred to as comparison between study
groups.
Statistically significant correlations are highlighted in bold character.
∗ CRP: C-reactive protein.
§ BMI: body mass index.
¥ PCOS: polycystic ovary syndrome.
Φ PLT: platelets.
# GDM: gestational diabetes mellitus.
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Table 3: Logistic regressionmodel showing the predictive value of C-reactive protein cutoff (>1.86 𝜇g/mL) toward overallmaternal outcomes.
Univariate model Multivariate model
OR∗ 95% CI§ 𝑝-value OR 95% CI 𝑝-value
Maternal adverse outcome
CRP¥ >1.86 𝜇g/mL 2.80 1.77-4.43 <0.001 2.93 1.83-4.69 <0.001
Age 1.09 1.04-1.14 0.001
GDMΦ 1.37 0.70-2.65 0.358
Hypertension 5.15 0.58-46.04 0.142
Statistically significant correlations have been highlighted in bold character.
∗OR: odds ratio.
§ CI: confidence interval.
¥ CRP: C-reactive protein.
Φ GDM: gestational diabetes mellitus.
Table 4: Linear regression showing the association between C-reactive protein and overall adverse outcomes (both maternal and neonatal).
Univariate model Multivariate model
𝛽 95% CI∗ p-value 𝛽 95% CI p-value
Overall adverse outcome
CRP§ 0.043 0.003-0.083 0.036 0.050 0.010-0.090 0.015
Age 0.007 -0.003-0.016 0.168
GDM¥ 0.129 -0.010-0.268 0.068
Hypertension 0.250 -0.066-0.567 0.121
Statistically significant p values are displayed in bold characters.
∗ CI: confidence interval.
§ CRP: C-reactive protein.
¥ GDM: gestational diabetes mellitus.
unit admission, and congenitalmalformations [34, 35]. In our
cohort, a positive association between serum CRP levels and
the development of maternal complications persisted even
whenmaternal age, GDM, and gestational hypertension have
been taken into consideration. An explanation may be found
in the limited number of women suffering from both GDM
and gestational hypertension. These findings encourage the
routine CRP dosage to better stratify pregnant women at high
risk of complications, independently of the presence of other
known risk factors.
Some limitations have to be acknowledged in our paper.
First of all, data on lifestyle habits and cardiovascular risk
factors, such as cholesterol levels and smoking habits, were
not available for the analysis and may have partially influ-
enced adverse outcomes. Secondly, serum samples have been
collected only at the time of OGTT andwe could not evaluate
possible changes of CRP until delivery. Finally, data have been
retrieved in a single center and this may limit the gener-
alization of our results, needing future multicenter studies
to confirm them on a larger number of patients. Finally,
although the clinical occurrence of infections has been
excluded, we cannot ensure the absence of asymptomatic
infections potentially altering CRP levels and influencing
pregnancy as no urine or blood culture has been performed.
5. Conclusions
Maternal CRP serum levels might be an effective and con-
venient tool to recognize women at high risk for pregnancy
complications, thus needing a closer follow-up. Further
studies are warranted in order to widen our knowledge
about pathophysiological mechanisms linking inflammation
and pregnancy complications, in particular by considering
the real impact of GDM in determining both maternal
and neonatal outcomes. In this view, we are planning to
consider only women with GDM in order to establish clearer
correlations between diabetes and adverse outcomes, maybe
evaluating glycemic values since the gestation beginning.
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